Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
PDX1328 Buparlisib
10.0
pan PI3K
PI3K/mTOR
 -0.5321 0.29075
CAL-51 Topotecan
10.0
Topo I
Chemotherapy
 -0.5303 0.69711
MDA-MB-453 Topotecan
10.0
Topo I
Chemotherapy
 -0.5289 0.30739
MDA-MB-361 INK-128
0.1
mTORC1/2
PI3K/mTOR
 -0.5285 0.39306
MDA-MB-134-VI Doxorubicin
0.1
Chemo
Chemotherapy
 -0.5278 0.23436
MDA-MB-361 Neratinib
3.1623
EGFR/HER2
RTK
 -0.5277 0.43595
MDA-MB-134-VI Etoposide
10.0
Topo II
Chemotherapy
 -0.5248 0.28314
MDA-MB-157 AZD7762
1.0
CHK1/2
Cell cycle
 -0.5246 0.50335
BT-20 Taxol
0.1
Chemo
Chemotherapy
 -0.5245 0.72716
MDA-MB-361 Volasertib
0.031623
PLK
Cell cycle
 -0.5223 0.45811
HCC70 Luminespib
0.1
HSP90
Misc
 -0.5219 0.47120
BT-20 Volasertib
0.1
PLK
Cell cycle
 -0.5218 0.70449
MDA-MB-468 Taxol
1.0
Chemo
Chemotherapy
 -0.5218 0.78956
HCC1500 Dinaciclib
0.31623
pan CDK
Cell cycle
 -0.5214 0.45852
HCC1395 Abemaciclib
10.0
CDK4/6
Cell cycle
 -0.5202 0.43342
HCC1395 Topotecan
3.1623
Topo I
Chemotherapy
 -0.5190 0.48804
CAL-51 AZD7762
10.0
CHK1/2
Cell cycle
 -0.5186 0.71682
MDA-MB-361 Etoposide
10.0
Topo II
Chemotherapy
 -0.5173 0.33322
PDX1328 Buparlisib
3.1623
pan PI3K
PI3K/mTOR
 -0.5173 0.32988
PDX1328 Doxorubicin
1.0
Chemo
Chemotherapy
 -0.5160 0.24460
MDA-MB-468 Buparlisib
10.0
pan PI3K
PI3K/mTOR
 -0.5157 0.71614
MDA-MB-468 Taxol
0.31623
Chemo
Chemotherapy
 -0.5157 0.78107
HCC70 Tivantinib
3.1623
MET
RTK
 -0.5148 0.53681
MDA-MB-134-VI Taselisib
10.0
PI3Ka, g, d
PI3K/mTOR
 -0.5146 0.30851
MDA-MB-468 Etoposide
10.0
Topo II
Chemotherapy
 -0.5132 0.66461